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Abstract
In patients with cystic fibrosis (CF), early intervention and prevention of lung disease is of paramount importance. Principles to achieve
this aim include early diagnosis of CF, regular monitoring of the clinical status, various hygienic measures to prevent infection and cross-
infection, early use of antibiotic courses in patients with recurrent or continuous bacterial colonisation and appropriate use of chest
physiotherapy.
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1. Introduction
Cystic fibrosis (CF) is the most common autosomal
recessive lethal hereditary disorder in Caucasians [1]. The
prognosis of the disease is substantially dependent on
chronic respiratory infection and inflammation, a hallmark
of CF. Pseudomonas aeruginosa is the dominant pathogen
today in patients with CF [2]. During the last decades, a
variety of treatment strategies have been developed, includ-
ing improved antibiotic therapies, which have had a signif-
icant positive impact on prognosis. The median survival age
of individuals with CF in industrialized countries increased
from 14 years in 1969 to more than 30 years in 2001 and
approximately 37% of patients are 18 years of age or older
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However, during the last 5 years, reported survival rates
appear to have reached a plateau in some industrialized
countries (e.g., Ref. [2]). The objective of this consensus
document is to overcome this possible development by
outlining further strategies to substantially increase life
expectancy in CF. These include (1) neonatal screening of
the general population to identify CF, (2) early initiation of
antimicrobial and anti-inflammatory therapy in identified
patients, (3) implementation of effective hygienic measures
inside and outside of CF centres, and, (4) establishment of
patient registries.
Neonatal screening programmes for CF have been
implemented in several countries with a high incidence of
CF, such as New Zealand, Australia, Austria, France,
Northern Ireland, Scotland, Wales, some regions of England
and some states in the USA. Early identification of patients
with CF by neonatal screening reduces the time to diagno-
sis to a few weeks after birth. Clearly, any therapeutic
approach can be initiated much earlier in identified patients,
particularly antimicrobial therapy, since bacterial lung
infections may start very early in the life of an infant with
CF. Optimizing antibiotic therapy against the major CF
pathogens and anti-inflammatory therapy is of the highest
priority, since lung disease has a major impact on the
prognosis of patients. Some years ago, the ECFS and UK
CF Trust issued recommendations for the antibiotic treat-
ment of P. aeruginosa [5,6]. However, much work has been
done since then, and the present document will summarize
the latest developments including strategies against patho-
gens other than P. aeruginosa. In addition, improved anti-
inflammatory therapy, mucolytic therapy and airway phys-
iotherapy as adjuncts to antibiotic therapy become more
and more important and results will be presented here. Our
growing knowledge regarding the transmission of bacterial
pathogens from infected patients, contaminated healthy
individuals, or the inanimate environment to patients with
CF has resulted in the implementation of better infection
control policies within CF centres to minimize transmission
of infection between patients. Finally, due to the heteroge-
neity and changing epidemiology of the disease, we rec-
ommend the collection of patient data in registries to obtain
sufficient statistical power to anticipate new developments
and trends and to optimize care. This document provides a
summary of the relevant data and evidence-based recom-
mendations for the early intervention and prevention of
lung disease in patients with CF to improve care in CF
centres.
2. Screening
Population screening for CF can be carried out with the
aim to identify CF carriers or patients. The goal of hetero-
zygote screening is to provide carrier couples with the
information that allows them to make an informed choice
in family planning [7]. The ultimate goal of CF carrier
screening is to reduce the number of CF births on a
population level. However, there is little evidence that
couples carrying the CF gene will actually avoid giving
birth to an affected child. Nevertheless, since antenatal
screening was offered for CF in Scotland, the number of
births has fallen dramatically, indicting that in this area
affected couples choose therapeutic abortion. Heterozygote
screening can be offered preconceptionally or to the preg-
nant woman. According to recent guidelines, it is recom-
mended that prenatal screening for CF is offered to every
pregnant woman in the USA, but there is concern that the
benefits and risks of these guidelines have not been inves-
tigated [8]. The objective of neonatal screening is to detect
infants with CF as early in life as possible [9]. In infants
with CF identified by neonatal screening, standard care may
be initiated more rapidly than in CF infants diagnosed by
symptoms and this may offer clinical benefit. Neonatal
screening will allow early genetic counselling, specifically
before the conception of another potentially affected child,
and eventually may lead to changes in the reproductive
behaviour of couples and their child bearing relatives with a
first affected child [10,11]. Furthermore, it may be of benefit
to parents by removing the stress of a delayed diagnosis
[12].
Neonatal screening for CF has been implemented in
several parts of the world [13]. Immunoreactive trypsino-
gen (IRT) followed by mutation analysis in samples with
increased concentrations of IRT has proven to be a proce-
dure with a high sensitivity as well as specificity in the
diagnosis of CF [14]. Multiple CFTR alleles should be
included to increase the sensitivity and the specificity of
newborn screening programs employing two-tier testing
with trypsinogen and DNA analysis [15,16]. Population-
based studies have demonstrated [17] that CF diagnosed in
the first weeks of life, before the appearance of symptoms
results in better clinical condition later. For instance, in the
Veneto region of Italy the rate of screening increased
progressively from 1970 and currently ranges from 98.4%
to 99.1% with a median time from birth to confirmation of
diagnosis of 32 days (range: 0–1531) (B. Assael, personal
communication).
The effects of neonatal screening on clinical outcome are
more cumbersome to assess [7]. A blinded, prospective and
randomized study [18,19] demonstrated that early recogni-
tion of the disease has nutritional benefits in the first years
of life, at the time when growth is most rapid. After delayed
diagnosis of CF, malnutrition may persist and catch-up may
not be possible [19]. Poor nutritional status will be the
results of delayed onset of enzyme substitution as well as
delayed diagnosis and treatment of the lung infections.
Several prospective cohort and controlled, but not random-
ized, studies have shown that neonatal diagnosis decreases
the rate of hospitalisation [20,21] and leads to better clinical
scores in childhood [12,22–25].
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asymptomatic diagnosis (<6 weeks of age) did not influ-
ence the rate of chronic infection by P. aeruginosa, a major
factor in lung disease progression [26], probably reflecting
the innate increased susceptibility of the CF airway for
colonisation with opportunistic environmental pathogens
and variable early treatment policies. Recent data in the
UK CF Database also suggests that up to the age of 2 years,
no benefit was observed for patients identified by screening
in terms of the likelihood of acquisition of P. aeruginosa
(Mehta et al., unpublished). However, in contrast to the
American study [26], after the age of 2, significantly fewer
patients diagnosed by screening had one or more P. aeru-
ginosa positive cultures than those clinically diagnosed.
This might be related to the opportunity screening offers
to start treatment after the first acquisition of this pathogen.
Improved survival for screened as compared to clinically
diagnosed patients has been reported. For patients born
between 1973 and 1980, survival rates of 88% and 80%
in a screened group versus 60% and 50% in a clinically
diagnosed group at age 11 and 24 years, respectively
(excluding patients diagnosed by presence of meconium
ileus), have been observed [23,27]. However, survival can
no longer be used as a marker in this context because of the
extended life expectancy following the more effective use of
antibiotics, and improved nutritional management including
supplementation with more effective acid resistant pancre-
atic enzymes, which has changed CF management since the
mid-1980s. However, mortality in early infancy or child-
hood may be prevented using screening [28,29].
Furthermore, the median age of diagnosis of CF because
of symptoms has been as low as 0.5–1 year of life in many
regions, which differs substantially from neonatal screening
allowing a diagnosis of CF around a median age of 4 weeks.
Median life expectancy of patients with CF presently lies
around the age of 30 years. Therefore, it is improbable that a
diagnosis by neonatal screening has a large influence on
survival. Besides CF is a heterogenous disease, and many
factors may have influenced outcome over such a long
period. Indeed, in a cohort study no significant difference
in the overall cumulative probability of survival between
patients diagnosed by neonatal screening or after symptoms
has been observed in one area, although the survival curve
of the patients detected by screening seemed to be the best
[30]. It should be noted also that patients now aged 25 years
and older did get their initial treatment in the mid 1970s,
before acid resistant pancreatic enzyme replacement therapy
was available.
Therefore, surrogate clinical measurements such as
height, weight, lung function or microbiological status,
rather than survival outcomes are better indicators of the
benefit afforded by screening particularly during the first 10
years after birth when screening would be expected to have
the greatest effect [17,18,27,31]. However, clinical benefit
from neonatal screening is dependent on adequate treatment
and the failure to provide an adequate standard of care after
a diagnosis of CF has been made probably is a critical
factor in outcome [32]. For example, a recent neonatal
screening programme in CF [21] was not supported by
initiation of a community based plan of optimised inter-
vention at the time of diagnosis resulting in no clinical
advantage.
In conclusion, it seems sufficiently clear that neonatal
screening improves nutrition and growth, and probably
leads to an improved lung function in the first 10 years of
life. Other advantages are the low costs of screening. Early
genetic counseling gives parents the choice of avoiding the
birth of another child with CF [10] and leads to a reduction
of the number of births of patients with CF on a population
level [11]. Moreover, a short diagnostic delay appeared to be
beneficial for parents with a child with CF [12].T h e
advantages of neonatal screening for CF while the proce-
dure carries no harm of its own have led to the recommen-
dation to consider screening for CF in every country with a
routine neonatal screening programme and a high incidence
of CF [11,20,33].
3. Early diagnosis of airway disease
The objective of early diagnosis of bacterial lung colo-
nization/infection is to implement antibiotic therapy more
rapidly, or even introduce it prophylactically, with the aim of
influencing the outcome for the patient with CF. The
spectrum of microbial pathogens in CF lung infections
differs considerably from that of other patients with chronic
lung disease. Many environmental bacteria are found in CF
airway infections, including S. aureus, P. aeruginosa, Sten-
otrophomonas maltophilia, B. cepacia complex, fungi,
atypical mycobacteria, whereas Streptococcus pneumoniae,
H. influenzae or Moraxella catarrhalis and bacteria of the
endogenous flora, which are often present in other lung
diseases, are found less frequently. Furthermore, due to the
chronic course of lung disease, bacterial pathogens such as
S. aureus or P. aeruginosa change their phenotype and
mucoid or small colony variants [34] are often observed
which are not easily recognized by laboratories not special-
ized in CF microbiology. In addition, the stress of the local
lung environment leads to the occurrence of hypermutable
bacterial strains, which show a large variety of genotypic
and phenotypic traits including resistance to antimicrobial
drugs. Thus, sensitive and highly resistant colonies of a
given strain may be present simultaneously in one sputum
specimen. Since infection in patients with CF is often
polybacterial, selective agars have to be used, particularly
for S. aureus, H. influenzae, P. aeruginosa, B. cepacia
complex and atypical mycobacteria ([5,35]; Table 1). Fi-
nally, the early diagnosis of lung infections in patients with
CF is difficult, since lung infections are often already
present in small children and infants not expectorating
sputum [36–39]. Consequently, other methods such as
nasopharyngeal aspirate, cough swabs, sputum induction
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ical tests [42–44] have a role in diagnosis.
4. Patient registry
In patient registries (databases), clinical and epidemio-
logical data from patients in a centre, a country or a region
(such as Europe) are regularly collected to compare care and
life expectancy of patients with CF between centres and
countries and to observe trends in the changing epidemiol-
ogy of the disease over time. Several CF registries have
been developed [2,3,45–52]. Patient data collected in reg-
istries are meant to observe longitudinal changes in a given
clinical/demographic parameter and to determine similari-
ties/differences between centres/countries/regions at a given
time for such parameters. This leads to analysis of the
determinants for such similarities/differences resulting in
changes and improvements of care.
Registry data help to establish descriptive statistics and
demographic figures important as a basis for improvement of
CF management and care. National and international regis-
tries should be linked in order to come to common methods
of evaluation and to create more effective international
guidelines. In addition to descriptive statistics, patient regis-
tries are a good basis for quality management including
reports focussing on the quality of care in different institu-
tions or cooperative groups. Quality ranking and benchmark-
ing are identifying centres of excellence. Learning from best
practice is a tool of quality management as well as a way of
defining alarm signs and creating decision trees in defined
situations of complication or deterioration. Quality groups
can help to establish consensus statements and guidelines
based on best practice.
Patient registries and quality management cannot replace
scientific studies. For instance, representativity (annual re-
turn of data sheets) has been as low as 80% in Germany
[3,49]. However, important questions can be asked and
trends can be indicated that have to be checked by scientific
studies. Most importantly, outcome data on different levels
(survival, lung function, nutrition, microbiology) have to be
compared with regard to different therapeutic strategies (e.g.,
centre care, antibiotic treatment, nutritional support). By
longitudinal comparison predictive indicators in CF can be
defined [53].
Registries are particularly important for CF, since the
clinical disease spectrum is largely heterogenic and the
outcome or clinical course is probably influenced by a
variety of modifier genes [1]. Additionally, environmental
factors may affect disease severity. Thus, certain CF sub-
populations may only be detectable in large patient regis-
tries. Additionally, changes in the prevalence of CF
pathogens important for the life expectancy of patients with
CF are observed much earlier in the larger patient cohorts
found in registries than in small patient cohorts. For exam-
ple, while S. aureus and H. influenzae were the most
prevalent pathogens in the pre-antibiotic era [54] and
represented the major causes of morbidity and mortality in
infants with CF at that time, P. aeruginosa is the dominating
pathogen today [2]. However, this picture may change
again. S. maltophilia, Achromobacter (Alcaligenes) xylosox-
idans, Aspergillus fumigatus, non-tuberculous mycobacteria
(NTM) and respiratory viruses are regarded as more and
more important in the pathogenesis of lung disease in
patients with CF.
Clearly, registries are expensive, and sponsorship for data
collection and analysis is needed. In addition, a patient
registry should be easily and rapidly accessible (possibly
by Internet), and should contain anonymous and standard-
ized data, which can be compared with other registries.
5. Strategies to eradicate bacterial pathogens from CF
airways
The rationale for the question is that antimicrobial
treatment may be necessary only when a microorganism is
regarded as pathogenic in the CF airways. However, prob-
ably every microorganism whether regarded as a pathogen
or not should be treated, since it causes inflammation which
could damage airways. To determine if a microorganism is
truly pathogenic in patients with CF an association of the
organism with acute pulmonary exacerbations, increasing
Table 1
Selective agars for identification of S. aureus, H. influenzae, P. aeruginosa,
B. cepacia complex and atypical mycobacteria
Organism Recommended media or processing
a
S. aureus Mannitol salt agar
Columbia/colistin-nalidixic agar
H. influenzae Chocolate agar (supplemented or not with 300
mg/l bacitracin) incubated anaerobically
P. aeruginosa MacConkey agar, Difco Pseudomonas
Isolation Agar
B. cepacia complex BCSA, Mast cepacia agar
S. maltophilia MacConkey agar, synergistic inhibition of
beta-lactamase by aztreonam and clavulanic
acid h-lactamase facilitates indification
A. xylosoxidan MacConkey agar
Mycobacterial
species other than
tuberculosis (MOTT)
Decontamination step with 0.25% N-acetyl-L-
cysteine and 1% NaOH followed by 5% oxalic
acid, culture on Lo ¨wenstein-Jensen medium
Aspergillus spp. Aspergillus spp. and other molds grow well on
horse blood agar or Sabouraud agar selective
for fungi
Other Gram-positives Horse- or sheep blood agar, may be
supplemented with neomycin and gentamicin
(streptococcal selective agar)
Other Gram-negatives MacConkey agar
For routine culture: Horse-blood agar, chocolate agar, MacConkey agar,
mannitol salt agar, PC agar and Sabouraud agar. If acid fast bacilli are seen
by microscopy: decontamination and Lo ¨wenstein-Jensen agar.
a Detection of some pathogens may be enhanced by prolonging
incubation for as long as 4 days to allow slow-growing colonies to become
apparent. All media are commercially available.
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tion chest CT images, development of an antibody response
[55], a chronic decline in pulmonary function, and/or
increased mortality has to be established [56]. The epide-
miology of microbial pathogens in CF airways has changed
over decades. Factors which may contribute to this change
involve (1) antibiotic treatment, (2) increasing age of
patients, (3) increased use of inhalation therapy combined
with insufficient hygiene, and (4) evolution of the bacterial
pathogens themselves.
5.1. Microbial pathogens
S. aureus is often the first microorganism isolated from
CF sputum or cough swab in infants not receiving long-term
anti-staphylococcal prophylaxis [2]. It was already recog-
nized as a CF pathogen in the pre-antibiotic era [57] when it
was responsible for the premature death of the majority of
CF children [54]. The occurrence of methicillin resistant S.
aureus (MRSA) strains among patients with CF in the last
decade is particularly threatening [58], although at present
does not seem to have clinical significance [59]. P. aerugi-
nosa, particularly the mucoid colonial morphotype, was
recognized as a pathogen in the 1970s [60]. In the majority
of patients with CF producing sputum and carrying mucoid
P. aeruginosa, the infection causes an immediate and more
rapid reduction of lung function than in patients with CF
without P. aeruginosa infection [55,61]. Higher sputum
volumes are correlated with a greater degree of inflamma-
tion, higher neutrophil numbers and released serine protei-
nases and hence a greater degree of lung obstruction and
destruction. Conversely, antibiotic treatment for P. aerugi-
nosa in patients with CF had a positive effect on clinical
condition, pulmonary function, P. aeruginosa colony counts
in sputum, inflammatory markers, quality of life, nutritional
status and survival of the patients [62–64].
Nonencapsulated H. influenzae has been recognized as a
pathogen in CF for many decades [65] due to improved
identification methods and selective conditions. It frequently
persists in the lungs of patients with CF for prolonged
periods of time and specific antibodies are found in the
sputum and sera of these patients. Clear evidence of a
pathogenic role for H. influenzae in individuals with CF is
provided by measurement of inflammatory markers. In one
study, some of the highest concentrations of C-reactive
protein measured (>400 mg/l serum) were associated with
acute exacerbations and culture of H. influenzae at >10
8
CFU/ml sputum [66]. Penetration of H. influenzae in
epithelial cells may contribute to the persistence of this
microorganism in patients with CF [67,68].
The B. cepacia (previously named Pseudomonas cepa-
cia) complex is a group of at least nine closely related
bacterial species [69,70], which emerged as CF pathogens in
the last two decades. Many reports have confirmed that B.
cepacia genomovar III (now known as B. cenocepacia)i s
highly transmissible and virulent in patients with CF [71];
infection with B. cepacia complex is associated with a
markedly shortened median survival [47,53,72]. The ‘‘B.
cepacia syndrome’’ is characterized by high fever, bacter-
emia, rapid pulmonary deterioration and death. Although
infection with B. cepacia complex is generally chronic, in
some patients with CF, infections may be transient.
S. maltophilia (previously named Pseudomonas malto-
philia and subsequently Xanthomonas maltophilia) has been
detected in sputum specimens of patients with CF. However,
whether its detection is correlated with increased morbidity
or mortality is unclear based on published evidence [73–
77]. S. maltophilia prevalence rates vary considerably
between CF centres with a mean prevalence rate of 4.3–
6.4% [2,4] but up to 10% to 25% in single centres [76–78].
As with S. maltophilia, the opportunistic human patho-
gen A. (previously Alcaligenes) xylosoxidans has also been
recovered with increasing frequency from respiratory tract
cultures of patients with CF over the last decade [2]. Its
pathogenicity in patients with CF is also rather unclear
although an association of A. xylosoxidans with pulmonary
exacerbation has been reported [79]. The prevalence rate of
A. xylosoxidans recorded in clinical trials on inhaled tobra-
mycin was 8.7%.
The prevalence of NTM has been determined as 13%
(range: 7–24%) [80]. Mycobacterium avium complex
(72%) and M. abscessus (16%) were the most common
species [80]. The observation that patients with CF with
repeated sputum isolates of non-tuberculous mycobacteria
may develop typical clinical signs of mycobacteria disease
[80–82], and show clinical improvements after courses of
antimycobacterial therapy, supports the notion that NTM
may be pathogens in CF [80,83–85]. Older age was the
most significant predictor for isolation of NTM [80].
The virulence of A. fumigatus has been clearly estab-
lished in patients with CF from 1970. Patients with CF
produce specific antibodies against the microorganism [86],
and A. fumigatus, as well as more rarely other fungi, may
cause allergic bronchopulmonary aspergillosis (ABPA) in
approximately 2% to 7.8% of patients with CF [87,88].
Aspergilloma or invasive aspergillosis is rare [89,90].
Respiratory viruses have been recognized since the early
1980s in CF. Respiratory viral disease can be more severe in
patients with CF than non-patients with CF and can con-
tribute to the progression of lung disease [91–96]. RSV
infections have been shown to be associated with a rise of P.
aeruginosa antibodies in patients who harboured these
bacteria [97]. RSV can cause severe acute illness in patients
with CF and persistent morbidity [92,96]. Influenza infec-
tion has also been associated with respiratory deterioration
and increased hospitalization among patients with CF
[94,98,99]. Adenovirus, rhinovirus and parainfluenza
viruses have been associated with respiratory illness
[92,96]. The impact of rhinoviruses on patients with CF is
unclear at present. There is some evidence that viral
respiratory infections predispose the CF lung to bacterial
infection [95,96,100].
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Most initial P. aeruginosa are nonmucoid, and in general
completely susceptible to pseudomonal-specific antibiotics
when they are contracted from the environment. In addition,
plug formation and, hence, sputum production is often
minimal when P. aeruginosa is only colonizing the airways.
Therefore, early treatment of P. aeruginosa (shortly after
assessment of P. aeruginosa lung colonization) may pre-
serve lung function [101–103] and lead to eradication of the
pathogen [103–105]. However, without treatment, this
pathogen often persists in the CF airway.
Accumulated evidence since the 1960s indicates that
mucoid P. aeruginosa phenotypes originate from the non-
mucoid colonising strain by a variety of genetic, environ-
mental and selective influences including mutation [106] and
growth in viscous anaerobic/microaerobic mucus [107].I n
addition, other mechanisms for this phenotypic switch have
been demonstrated in vitro [108]. Oxygen limitation and low
metabolic activity in the interior of the bacterial biofilm
correlate with poor antibiotic activity against biofilm bacteria
[109]. The exact time period in which P. aeruginosa adapts
to the CF lung by switching to mucoidy is not known.
However, in one episode where it was possible to accurately
document acquisition of environmental P. aeruginosa from a
hydrotherapy pool, mucoidy was detected within 3 months
[110]. Mucoid P. aeruginosa phenotypes carrying mutations
in alginate repressor genes are uniformly present in chronic
infection; however nonmucoid variants can also be found
[60], representing the original colonising strain or non-
mucoid revertants arising from mutations in alginate struc-
tural or regulatory genes [106]. These factors including (1)
alginate production leading to a mucoid colonial morphotype
in vitro or (2) antibiotic resistant bacterial phenotypes, (3)
lung abcesses, and (4) airway mucus plug formation impede
the eradication of pathogens from CF airways by antibiotic
therapy.
Mucoidy of S. aureus in CF airways [111] is also
triggered by anaerobic conditions [112].F u r t h e r m o r e ,
NTM, which may be found in sputum specimens of patients
with CF, have the ability to form biofilms [113] as do S.
maltophilia and A. xylosoxidans. Mucoid P. aeruginosa and
possibly also mucoid S. aureus restrict the penetration of
most antibiotics, particularly the penetration of aminoglyco-
sides and two to three orders of magnitude higher tobramy-
cin concentrations are needed to be comparably effective
against P. aeruginosa biofilms compared with its nonmucoid
variant [114].
However, non-mucoid P. aeruginosa can be more
resistant to antibiotics than their mucoid variants [115].
Thus, for many reasons, antibiotic therapy for chronic
bacterial lung infections in patients with CF generally only
achieves a reduction of P. aeruginosa colony counts rather
than complete eradication. Due to the stresses imposed by
the host defense system and by repeated antibiotic treat-
ments, hypermutable strains of P. aeruginosa develop in
CF airways [116,117], and result in rapid antibiotic resis-
tance thus contributing to the impairment of bacterial
eradication. In general, during the chronic course of the
infection, P. aeruginosa colonies become increasingly re-
sistant to antimicrobial agents making therapy progressively
less effective.
Finally, negatively charged glycoproteins and human
DNA in plugs formed as a consequence of neutrophil
influx and decay may restrict bacterial clearance. Plugs
may bind positively charged aminoglycosides such as
tobramycin [118] and cause obstruction. With the exception
of B. cepacia complex, P. aeruginosa is thought to trigger
more obstruction/inflammation than the other CF-related
pathogens.
5.3. Eradication trials of P. aeruginosa and S. aureus
The initial report of the feasibility of reducing both the
number of P. aeruginosa organisms isolated and also the
frequency of isolation from the respiratory tract cultures of
the treated patients by using nebulised colistin for early P.
aeruginosa colonisation [119] was confirmed in an single-
blinded, controlled, randomized study, using combined
treatment with aerosolized colistin and oral ciprofloxacin.
This significantly reduced the onset of chronic P. aeruginosa
infection in treated patients with CF compared to untreated
controls [104]. Similarly, a placebo controlled double-
blinded, randomized tobramycin inhalation study showed
that after onset of P. aeruginosa infection, the time of
conversion to a P. aeruginosa negative respiratory culture
was significantly shortened by active treatment, suggesting
that early tobramycin inhalation may prevent P. aeruginosa
pulmonary infection in CF [105]. A follow-up study using
historical controls [101] demonstrated that aggressive treat-
ment prevented or delayed chronic P. aeruginosa infection in
78% of the patients with CF for 3.5 years. After introduction
of early intensive antibiotic treatment, the probability of still
not having developed chronic P.aeruginosa infection 7 years
after the first isolation of P. aeruginosa was above 80%
[120]. Furthermore, aggressive treatment maintained or
increased pulmonary function during the year after inclusion
compared with the historical control group, in which pul-
monary function declined [101]. Data from three subsequent
studies also demonstrate that early treatment of P. aerugi-
nosa lung colonization effectively eradicates the pathogen
[103,121,122]. Unpublished data from Italy reveal that their
patients with CF may remain free of P. aeruginosa for a
mean of 2.4 years using colistin in combination with cipro-
floxacin (Taccetti et al., unpublished data). Other investiga-
tors have determined a median time to re-infection after
eradication of 8F5.7 months [123]. In order that antibiotic
therapy may be initiated early enough, before established
chronic infection, it is recommended that a respiratory tract
culture be performed at least quarterly, preferably every
month, and at any exacerbation of respiratory symptoms
[5]. Although it may be thought that the increased frequency
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cost of care, the opposite is the case. Early antibiotic
eradication therapy is much less costly than maintainance
therapy for chronic P. aeruginosa lung infection ([124];
Taccetti et al., unpublished data).
A major difficulty in relation to early therapy is obtaining
the scientific proof that P. aeruginosa is actually eradicated
from the lungs. Negative or decreasing serum antibody titers
[103], genotyping of P. aeruginosa [123] isolated at the next
episode of bacterial lung colonization revealing a different
bacterial genotype, and negative brochoalveolar lavage is
supportive evidence that eradication was achieved. The
recommended drugs and doses for early anti-pseudomonal
therapy in CF are given in Table 2. For some patients with
CF, it may not be possible to eradicate pathogens from their
airways for several reasons including that they attend the CF
centre only infrequently and consequently chronic infection
and biofilm formation become established before treatment
is initiated. Currently, a multicentre trial on P. aeruginosa
eradication therapy in Europe is carried out using preserva-
tive free tobramycin.
Many patients with CF are initially infected with S.
aureus. There is general agreement to treat such patients
with anti-staphylococcal antibiotics for 2 to 4 weeks
[1,125]. This may eradicate the organism [126,127].I n
culture positive patients, anti-staphylo-coccal treatment for
at least 2 weeks results in an eradication rate of f75% and
only a few patients harbour S. aureus for more than 6
months thereafter [127]. In another study, 57% to 21% of
colonized/infected individuals still harboured the same S.
aureus genotype when checked after 3 and 19 months,
respectively [126]. S. aureus may persist intracellularly as
small colony variants; these variants are often missed on
routine cultures and may revert to normal strains after
cessation of antibiotic treatment [34]. Whether the occur-
rence of MRSAwill lead to a change of this epidemiological
picture is not clear. If short-term courses of anti-staphylo-
coccal therapy fail, longer treatment courses (1–3 months)
are necessary [60]. The recommended drugs and doses for
anti-staphylococcal therapy in CF are given in Table 3.I n
patients with CF infected with H. influenzae, recommended
eradication therapy is 2–4-week courses using specific
antibiotics as listed in Table 4.
5.4. Management of chronic bacterial and fungal lung
infection
The optimal management of chronic P. aeruginosa lung
infections in patients with CF has been outlined recently
[5,6]. Briefly, due to the endobronchial location of the P.
aeruginosa infection in patients with CF and the inaccessi-
bility of mucoid P. aeruginosa in plugs, high doses of
intravenous antibiotics are recommended. To reach high
airway concentrations, colistin or aminoglycosides are gen-
erally administered by inhalation for maintenance therapy.
During acute exacerbations, intravenous application is pre-
ferred. Penicillins, cephalosporins, monobactams, carbape-
nems, aminoglycosides and sometimes colistin are
administered intravenously (for other classes of antibiotics,
see Ref. [5]). Since patients with CF are treated with
antibiotics for most of their lives, monitoring for side effects
Table 2
Recommended drugs and doses for early anti-pseudomonal therapy in CF
Antibiotic Route of
administration
Dose Number of
administrations
per day
Ciprofloxacin p.o. 20–30 mg/kg 2
Colistin inhaled
a 2–3 Million U
b 2–3
Tobramycin inhaled
a 80–300 mg
c 2
a Provided that the inhalation technique is effective and mouthpiece is
used.
b 1 mg colistin base=30.000 units.
c Preferably preservative free tobramycin, such as TOBI.
Table 3
Recommended drugs and doses for anti-staphylococcal therapy in CF
a
Antibiotic Route of
administration
Dose
(mg/kg/day)
Number of daily
administrations
Flucloxacillin oral 100 3
Dicloxacillin oral, i.v. 50 3–4
Fusidic acid oral, i.v. 25–50 2–3
Clindamycin oral, i.v. 20–40 2–4
Rifampicin oral, i.v. 15 2
Vancomycin i.v. 40 2
Teicoplanin i.v. 10 1
Linezolid oral, i.v.(<5 years) 10 3
Linezolid oral, i.v.(>5 years) 20 2
Moxifloxacin oral, i.v.(adults) 5–10 1
a Combination therapy is recommended using dicloxacillin+fusidic
acid or dicloxacillin+clindamycin. For pathogens difficult to treat such as
MRSA, rifampicin+fusidic acid or rifampicin+clindamycin can be used.
Linezolid is an expensive drug and clinical experience is limited. It should
also be used in combination with another drug due to the risk of
development of resistance. Other drugs listed should be used for
combination therapy of MRSA. Probenecid 15 mg/kg orally is recom-
mended to delay the renal excretion of h-lactam antibiotics.
Table 4
Recommended antibiotics for eradication therapy against Haemophilus
influenzae in patients with CF
Antibiotic Route of
administration
Dose
(mg/kg/day)
Number of daily
administrations
Amoxicillin oral 50–100 3
Pivampicillin oral 35
Amoxicillin/ oral 50–100
clavulanic acid 12.5–25 3
Ciprofloxacin oral 20–30 2
Rifampicin
a oral 15 2
Cefuroximeaxetil oral 20–30 2
Azithromycin oral 10 1
Clarithromycin oral 15 2
Probenecid 15 mg/kg orally is recommended to delay the renal excretion of
h-lactam antibiotics
a Only in combination with other antibiotics due to high risk of
development of resistance.
G. Do ¨ring et al. / Journal of Cystic Fibrosis 3 (2004) 67–91 73of antibiotic therapy should be carried out regularly. When
antibiotic therapy is started before susceptibility patterns are
available, the therapy has to be adjusted accordingly when
no clinical improvement is achieved. Whether patients with
CF should be treated for prolonged periods of time with
antibiotics to which P. aeruginosa is resistant remains
unclear. Due to an increase in antibiotic resistance of P.
aeruginosa strains after inhaled tobramycin therapy, an
intermittent regimen is currently used. To avoid or postpone
antibiotic resistance and for synergy reasons [5], combina-
tion therapy is widely used in patients with CF.
Major problems for optimal antibiotic therapy are B.
cepacia complex, S. maltophilia and A. xyloxidans all of
which are usually inherently multiresistant. With these
pathogens, combination therapy with antibiotics, shown to
be active as single agents in vitro, should be used in 2–4-
week courses (Table 5). However, more studies are needed
to further optimize therapy.
The treatment of ABPA relies on steroids such as
prednisone. The role of concomitant anti-fungal therapy
such as itraconazole, voriconazole, caspofungin or liposo-
mal amphoreticin [128] is presently unclear, although clin-
ical and serological effects have been observed [129].
Therapeutic trials for respiratory virus infections in patients
with CF have not been performed and prevention by
vaccination is regarded as important.
5.5. Prophylactic antibiotic treatment
The use of prophylactic antibiotics in an attempt to
prevent infection has been suggested, since lung infections
with other microorganisms including viruses may pave the
way for P. aeruginosa acquisition. On the other hand, it is
thought that an increased incidence of P. aeruginosa may
result from frequent use of antibiotics, since broad spectrum
antibiotics, in particular, may depress the normal pharyngeal
flora and lower the resistance to Gram-negative infection
[43,130]. In the USA, P. aeruginosa colonized or infected
the CF airway before the age of 3 years in 97% of the patients
[38]. This may be primarily related to the increased innate
susceptibility of the CF airway for colonisation with envi-
ronmental opportunistic pathogens. Prophylactic anti-staph-
ylococcal therapy with flucloxacillin initiated from the time
of diagnosis has been assessed in a controlled study [131].
Flucloxacillin treatment resulted in a lower rate of S. aureus
positive cultures, less cough and a lower rate of hospital
admissions during the observation period. This was the only
study carried out in patients diagnosed by neonatal screen-
ing, in whom treatment was probably started before the first
colonisation with P. aeruginosa. Continuous anti-staphylo-
coccal therapy was associated with a higher rate of P.
aeruginosa acquisition, especially in the first 6 years of life,
in a retrospective analysis [132]. However, nearly half these
patients were prescribed cephalosporins. Similarly, a placebo
controlled multicentre study of prophylactic cephalexin
therapy from the time of diagnosis up to the age of 6 years
failed to demonstrate any beneficial effect of cephalexin on
pulmonary function but did lead to a higher incidence of P.
aeruginosa in treated patients [133]. P. aeruginosa infection
increases pulmonary inflammation and has a negative effect
on morbidity and mortality, when infection persists [134].
Whether this increased risk of P. aeruginosa chronic infec-
tion is specific for cephalosporins or also applies to some
other anti-staphylococcal agents is unclear.
6. Strategies to combat early lung inflammation in
patients with CF
6.1. Causes and consequences of lung inflammation
Inflammation is present in some patients with CF from
early infancy [40,135] and since untreated bacterial infec-
tions persist without antimicrobial treatment, inflammation
as a response to infection persists often after the clearance of
the infection [36,136]. Inflammation is detectable to a
variable degree in the majority of chronically infected
patients. Inflammation also increases prior to death [137].
Several hypotheses linking the basic defect in CF to bacterial
lung disease have been put forward [1]. The majority of these
suggest that inflammation is a consequence of infection (e.g.,
Ref. [39]). Due to the persisting bacterial pathogens or
products, a type III hypersensitivity reaction is provoked
Table 5
Recommended antibiotics for therapy against B. cepacia complex,S .
maltophilia and A. xyloxidans in patients with CF
a
Antibiotic Route of
administration
Dose
(mg/kg/day)
Number of daily
administrations
Doxycyclin oral 2–3 1
Sulfamethoxazol/
trimetoprim
oral/i.v. 50–100+
10–20
2–4
Ceftazidime i.v./inhal 150–200 3
Meropenem i.v. 120 3
Colistin
b i.v.
c 2–5 2–4
Tobramycin i.v.
c 5–10 1–2
Ciprofloxacin oral/i.v. 20–30 2–3
Moxifloxacin oral/i.v.
d 5–10 1
Amoxicillin/
clavulanic acid
oral/i.v. 50–100/
12.5–25
3
Aztreonam i.v. 150–250 3
e
Ticarcillin/
clavulanic acid
i.v. 200–300/
6–10
4–6
e
Piperacillin/
tazobactam
i.v. 200–240/
25–30
3–4
a These species are resistant to many antibiotics and easily become
resistant to antibiotics during treatment. Susceptibility testing must
therefore guide the choice of antibiotics and combination therapy is usually
recommended (for B. cepacia complex, three i.v. drugs are recommended).
Probenecid 15 mg/kg orally is recommended to delay the renal excretion of
h-lactam antibiotics.
b B. cepacia complex is always resistant to colistin.
c Recommended doses for inhalation, see Table 2.
d For adults.
e Aztreonam/ticarcillin/clavulanic acid combination therapy because of
synergism against S. maltophilia.
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bodies against bacterial antigens, formation of immune
complexes and the influx of neutrophils from the blood into
the airway lumen [5]. The decaying neutrophils form large
volume plugs leading to obstruction of CF airways. The
release of high extracellular concentrations of lysosomal
serine proteinases progressively impairs multiple defense
pathways in addition to endobronchial tissue destruction.
Chronic lung inflammation with episodes of acute exacer-
bations initiates several physiological and metabolic changes
with deleterious effects including weight loss, anorexia, and
metabolic breakdown. Cachexia, which may occur in
patients with CF [136], is caused by a set of cytokines that
work in concert and have multiple effects on the nutritional
state of the patient [138]. Several cytokines including TNF-
a, IL-1, IL-6 and IL-8 are elevated in CF BAL fluids [139].
Generally, bacterial infection and inflammation are confined
to the lung. However, occasionally immune complexes may
spill over to the blood stream causing arthritis and vasculitis.
Whereas the lungs appear normal at birth, bacterial infection
and inflammation will lead to small airway obstruction. As
the disease progresses FEV1 and vital capacity continue to
fall. Decline in lung function in the later stages of CF
correlates with prognosis. In chronically infected patients
even with optimal therapy and between exacerbations, lung
function decreases with time [36,64,140,141] and it is
thought that even a small decline of 1–2% per year is
deleterious in the life expectancy of the patients. To avoid
the decline in lung function, regular microbiological moni-
toring, early intensive therapy and also perhaps anti-inflam-
matory therapy, is warranted.
6.2. Diagnosis and monitoring of lung inflammation
So far, it has been proposed to evaluate lung inflamma-
tion by measuring markers of inflammation in the blood
and/or in the airways, and also to use lung function
measurements, chest radiographs as well as High Resolution
CT (HRCT) scan. However, the investigation of inflamma-
tory markers in the patient sera, such as C-Reactive Protein
(CRP), neutrophil elastase-alpha-1-antitrypsin complex
[142], and cytokines, may not reflect the inflammatory
status in the airways. In addition, lung function tests, chest
x-rays and HRCT scans are only indirectly indicative of
lung inflammation. HRCT scan may already show localized
signs of destruction as a consequence of inflammation when
lung function measurements still are normal [143]. Regular
recording of lung function at close intervals using sensitive
techniques in both children and adults is the most valid
measure to detect lower airway inflammation. BAL has
been used for these purposes [36,134,139,144,145]. The
presence of high concentrations of neutrophil enzymes
including elastase (NE) and myeloperoxidase (MPO)
[135,140], high cytokine levels [144,145] and an imbalance
of serine proteases and serine protease inhibitors [135] has
been demonstrated, and oxygen radical damage of the lung
tissue is also present in CF infants [146]. A major disad-
vantage of BAL is undoubtedly the invasive nature of the
procedure limiting sequential investigations. Therefore, the
collection of exhaled breath condensates (EBC) has been
suggested to detect and monitor the course of inflamma-
tory markers in CF and other airways diseases [147].
Volatile compounds such as hydrogen peroxide (H2O2)
[148], nitric oxide [149], 8-isoprostane [150] and isoprene
[151] have been measured in EBC from CF and other
patients. However, whether these markers of inflammation
can be used to monitor anti-inflammatory therapy in CF is
still questionable.
6.3. Anti-inflammatory treatment strategies
Several anti-inflammatory drugs have been tested in
patients with CF during the last two decades (reviewed in
Ref. [5]). These include corticosteroids such as prednisone
[152], which were associated with considerable side effects
when given at high doses for prolonged periods of time
[153] including a risk of persistent growth impairment
[154]. Corticosteroids are still the treatment of choice for
ABPA and short-term oral courses have demonstrated an
increase in lung function and decrease serum IgG and
cytokine concentrations [155]. The administration of in-
haled corticosteroids which may prevent side effects of this
class of drugs was efficient in a 3 months study [156], but
larger multicentre trials with higher doses given for a longer
time are needed [157–159] before their benefit may be
definitively proven. The concomitant use of budesonide and
itraconazol, however, may induce iatrogenic adrenal insuf-
ficiency [160] and Cushing’s syndrome has also been
observed [161]. From the various non-steroidal anti-inflam-
matory drugs, ibuprofen [162,163] has been successfully
evaluated in a large CF study. Its beneficial effect on lung
function is particularly evident in patients <13 years. The
LTB4-receptor antagonist BIIL 284 [164] is currently being
tested in a multi-national CF study. While animal studies
suggest beneficial effects of recombinant IFN-g [165,166],
studies in patients with CF with this drug are lacking.
Protease inhibitors such as recombinant secretory leuko-
cyte protease inhibitor (SLPI) have been tested in patients
with CF. rSLPI aerosol therapy in patients with CF caused a
marked reduction in IL-8 levels in the epithelial lining fluid
[167], however, high concentrations have to be given [168].
While a trial with aerosolized a1-PI in a small number of
patients with CF revealed promising results [169], larger
studies using human plasma derived a1-PI or transgenic a1-
PI [170] have not been published until now. In addition to
specific anti-inflammatory drugs, antibiotics such as macro-
lides may induce anti-inflammatory effects and have im-
proved lung function in CF adults and children with chronic
P. aeruginosa infection [171,172]. Long-term, low-dose
administration of macrolide antibiotics has been associated
with down-regulation of nonspecific host inflammatory
response to injury and promotion of tissue repair [173].
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inhibits the activity of antibiotic and other aerosolised drugs
[118,174]. Consequently, it has been suggested that antibi-
otic aerosolization should be preceded by physiotherapy,
bronchodilatators and mucolytic agents such as recombinant
human deoxyribonuclease (rhDNase) I.
When the sulphur bridges dissolving drug N-acetyl-cys-
teine has been tested in patients with CF, no major significant
effect on lung function or other clinical parameters was
observed [175]. RhDNase has been shown to solubilize CF
sputum [176] and to be clinically effective [177]. A multi-
national double-blind study in 968 adults and children with
CF showed that rhDNase reduced the number of exacerba-
tions of pulmonary symptoms, improved lung function and
was well tolerated [178]. A second multi-national, open-
label study conducted in 974 patients with CF with moderate
lung disease demonstrated that administration of rhDNase
was safe, well tolerated, and effective under conditions
reflecting routine clinical practice in patients with CF
[179]. Treatment of young patients with CF with rhDNase
maintained lung function and reduced the risk of exacerba-
tions over a 96-week period [141]. In the light of biofilm
producing microorganisms such as P. aeruginosa or S.
aureus, the observation that rhDNase also solubilizes bio-
films is interesting [180]. Furthermore, infection rates have
been shown to be significantly decreased in a rhDNase
treatedgroup of patients with CF compared to controls [181].
However, some mucolytic drugs may adversely influence
the activity of antibiotics [182]. In vitro, binding of tobra-
mycin to components of CF sputum in vitro was increased
after rhDNase, although bactericidal activity of sputum
dialysate was not altered [183]. On the other hand, it has
been proposed that rhDNase can promote mixing of bacte-
ria, antimicrobial agent and sputum [184] and improve gene
transfer [185–187] by improving penetration through spu-
tum. It has been suggested that rhDNase may liberate
cationic mediators such as neutrophil elastase bound to
DNA in the airways [188,189] and hypertonic saline may
potentiate neutrophilic inflammation. However, this hypoth-
esis has not been confirmed in clinical studies [190–192].
Hypertonic saline has been shown to improve mucociliary
clearance in patients with CF [193] and the clinical effects
compare unfavourably with rhDNase [194]. No clinical
benefit of hypertonic saline was observed during a long-
term randomized controlled trial [194].
7. Non-pharmacological interventions and application of
hygienic principles to prevent lung disease in patients
with CF
7.1. Reservoirs and routes of transmission of bacterial
pathogens
S. aureus colonizes the skin including theanterior nares of
approximately 30% of healthy individuals. Thus, transmis-
sion from healthy carriers to patients with CF most probably
via hand contacts is an important route. Nasal and lung-
infecting isolates typically have an identical genotype
[126,195]. Transmission of S. aureus within CF and non-
CF families is regularly observed [126]. Chronically infected
patients with CF generally harbour the same clone of S.
aureus f o ra tl e a s t1t o2y e a r s[126,196]. Healthcare-
associated transmission of MRSA from non-CF to patients
with CF and from CF patient to CF patient has been reported
and may be facilitated by hospitalization of patients with CF
on general pediatric or adult medical wards [197,198].
P. aeruginosa has been repeatedly isolated from soil,
plants and vegetables [199]. It is a salt-sensitive water
organism often recovered from polluted water sources,
seawater near sewage outfalls, hospital sink drains, toilets
and showers, dental equipment, ineffectively chlorinated
swimming pools and whirlpools, air humidifiers, sanitary
plumbing, and many medical devices and equipment which
contain water (for review, see Ref. [200]). P. aeruginosa is
sensitive to desiccation and light and hence short-lived in
aerosols and on dry surfaces [201]. However, P. aeruginosa
may survive considerably longer in the presence of protein
and other organic material, e.g., sputum [202,203]. Heating
to 70 jC destroys P. aeruginosa. Most individuals with
intact body surfaces and flora are resistant to P. aeruginosa
colonization [199]. However, antibiotic treatment may in-
crease human gut colonization with P. aeruginosa [204].
P. aeruginosa aerosols may be generated from some
contaminated reservoirs such as nebulizers, toilets, sink
drains, non touch taps and dental equipment, leading to
acquisition by patients with CF [201,205–210]. Close con-
tact with such contaminated reservoirs seems to be important
for the transmission of pathogens via aerosols, since survival
of P. aeruginosa in aerosols is restricted to a few minutes.
The microbial burden is highest the first time when water is
run or toilets are flushed in the morning probably due to
overnight multiplication of sink bacteria [201]. The high
identity of patient and sink strains in some studies is also
suggestive that sink strains may colonize patients or vice
versa [202,211–213]. Whirlpools and hot tubs frequently
harbour P. aeruginosa and thus present a high risk for CF
individuals [214,215]. Infection of patients with CF from a
hospital hydrotherapy pool has been described [214]. Swim-
ming pools, if correctly managed and disinfected by chlo-
rine, are free of or contain very little P. aeruginosa and
therefore are regarded as not hazardous. However, plastic
animals used in swimming pools may be contaminated with
P. aeruginosa [216]. Water containing tubing in dentist’s
equipment may also be contaminated with P. aeruginosa
[209,217–219].
P. aeruginosa can be detected from many sources in CF
centres [203,220] including hands of healthcare workers
(HCWs) and patients and in the air around patients with CF
during coughing [60,202,203,220,221]. Ingestion of P. aer-
uginosa-contaminated food [222] may lead to colonization
of the oropharynx or colonization of the gastrointestinal
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drinking water leads to intestinal colonization by P. aerugi-
nosa [204]. The use of antibiotics in hospitalized patients
may thus increase the incidence of P. aeruginosa-positive
stools. Whether such a mechanism led to an increased P.
aeruginosa acquisition rate in patients attending the multi-
centre cephalexin trial is not known [133]. An important
human reservoir for P. aeruginosa is the chronically infected
CF patient (see cross-infection).
B. cepacia complex bacteria are well-known soil and
plant microorganisms [199,223], but their distribution in
different natural habitats is poorly documented. This is
primarily due to the lack of sufficiently selective isolation
media, but also to the poor sensitivity of some of the
currently used selective media, to the initial slow growth
of B. cepacia complex bacteria upon these media, and to
the use of inadequate identification procedures. As a
consequence, there are few reports on their environmental
distribution [199,224–226]. Nevertheless, all B. cepacia
complex bacteria have been recovered from soil and water
samples [69] and the emergence of newly infected
patients carrying strains characterized by unique genomic
fingerprints convincingly suggests that environmental ac-
quisition must occur. In addition, cross-infection among
CF individuals has been reported numerous times [227–
231], An epidemic B. cenocepacia (genomovar III) strain
that colonises over 200 patients with CF in 31 cities in 24
states of the USA has been identified from agricultural
soil [232,233].
Similarly, a variety of genome-based typing systems
showed that a B cepacia genomovar I strain was clonal
with an isolate recovered from a CF patient [234]. The use
of B. cepacia complex in agriculture poses a threat to
patients with CF [223,234,235]. The organism was also
isolated from sinks and refrigerators in homes of patients
with CF and healthy families [236] and in hospital sinks
(Do ¨ring, unpublished). B. cepacia complex contamination of
both respiratory therapy equipment [237], antiseptics and
disinfectants [238] has also been demonstrated. B. cepacia
complex is not found in healthy individuals [239]. Like P.
aeruginosa [202], B. cepacia complex embedded in sputum
has prolonged survival on surfaces [240]. Whether airborne
transmission of B. cepacia complex via coughing of
infected patients occurs is unclear [241]. Misidentification
of a range of Gram-negative non-fermenters including A.
xylosoxidans, S. maltophilia and B. cepacia complex is
especially problematic and presents a challenge to effective
infection control in CF [69,242,243].
S. maltophilia is a typical water organism found in tap
water or water in dentist tubes [209,244]. Similarly, A.
xylosoxidans is found in water reservoirs [245]. Genotyping
of S. maltophilia and Achromobacter species in CF centres
has not yet indicated transmissability as a major problem
[79,246–248]. Although similar results have been published
for A. xylosoxidans [79], in two other studies one or more
patient pairs shared a single genotype of A. xylosoxidans
[249]. Well-designed epidemiologic studies on routes of
transmission are needed.
NTM are also found in several water reservoirs including
dental unit waterlines [250]. In patients with CF, multiple
nosocomial outbreaks of NTM have been reported due to
either inadequate disinfection/sterilization of medical devi-
ces or environmental contamination of medications or
medical devices [251]. Person-to-person transmission of
NTM has not been described except via inadequately
cleaned and disinfected medical devices [251,252]. Several
studies indicate that patients with CF may be infected with
these pathogens [80,85,253,254]. Antibiotic therapy has
been suggested to be a risk factor for NTM colonization/
infection in patients with CF [255].
Infections of patients with CF with ubiquitous Aspergil-
lus spp. from many environmental sources may be the
consequence of antibiotic therapy [35,256]. Fungal spores
may become aerosolized within hospitals particularly during
reconstruction [257,258].
Respiratory syncytial virus (RSV), influenza, parain-
fluenza, adenovirus and rhinoviruses are the most common
viruses of the respiratory tract and are transmitted primarily
via direct contact with infected persons or aerosolization of
infective droplets. Viral particles are introduced through the
mucous membranes of the eyes and nose of susceptible
individuals. There are no CF-specific transmission issues.
Unravelling transmission routes of microorganims is
generally difficult, since multiple routes are possible; these
include (1) direct patient-to-patient contact, (2) contacts
between patients and healthy carriers of the bacteria (e.g.,
hospital personnel) who acquired colonization from other
patients or from the environment, and (3) direct contact
between the patient and the environmental sources. Identi-
fication of sources, typing of the microorganism in question
and case-control studies are used to investigate the epide-
miology of a transmission route [259].
Most individual patients with CF retain the same clone of
P. aeruginosa throughout their lifetime [260,261] and cross-
infection can be demonstrated, especially between siblings.
However, the initial source of P. aeruginosa for most
patients remains unknown.
Reliable and highly discriminatory typing methods are
essential to any microbiological surveillance programme or
investigation of transmission routes. Since bacterial strains
may undergo substantial phenotypic changes during the
course of chronic infection in patients with CF (e.g., Refs.
[106,111,261,262]) most bacterial organisms today are
typed employing genetic methods. ‘Finger-printing’’ of
chromosomal DNA using pulsed field gel electrophoresis
(PFGE) or random amplified polymorphic DNA analysis
(RAPD) are often used [125,202,243,261,263–266]. Refer-
ence laboratories are essential to assure the quality standards
for species identification and strain typing and to perform
techniques not available at local level. Reference laborato-
ries also facilitate the identification of the spread of epi-
demic strains at national and international levels.
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The expression ‘‘cross-infection’’ is often used to de-
scribe outbreaks of infections with a single strain, implicat-
ing person-to-person transmission or acquisition from a
common contaminated source. In this sense, cross-infection
can result from a mechanism by which an infected patient or
a healthy individual contaminated with an opportunistic or
pathogenic microorganism transfers this microorganism to
another non-infected patient. Due to its presence on human
epithelia, transmission of S. aureus within CF and non-CF
families is regularly observed [126,267]. Healthcare-associ-
ated transmission of MRSA from non-CF to patients with
CF and from patients with CF to patients with CF has been
reported [197,198].
Many epidemiological studies using typing methods
demonstrate cross-infection between patients with CF with
P. aeruginosa [202,268–274]. Evidence for cross-infection
also comes from the observation that CF siblings often
harbour genotypically identical strains [271]. Hospital staff
and the air [221] may act as a vehicle of P. aeruginosa
transmission to patients with CF in the hospitals
[201,202,275]. Cross-infection has also been shown to
occur in summer camps between patients with CF
[263,271,276]. High prevalence of P. aeruginosa infection
makes cross-infection much more likely to occur than with
other CF related, prevalent pathogens as indicated by
mathematical models [269]. The exact transmission routes,
however, have not been detected and cross-infection has
also not been detected in some centres [277]. Whether these
discrepancies reflect strain-specific characteristics, centre
differences regarding conditions for cross-infection includ-
ing the size of the centre and the opportunities for contact
between patients with CF, is uncertain.
Like P. aeruginosa, several studies using genotyping
methods have shown the transmission of B. cepacia com-
plex from patient to patient in both healthcare and non-
healthcare settings [110,227,229,230,278–281]. Transmis-
sion is facilitated by prolonged direct or indirect contact.
Infected patients with CF may cough and thus create
bacterial contaminated aerosols, which then may colonize
other patients [282]. However, such a transmission route
was not supported in other studies [202,283]. B. cepacia
complex strains may remain endemic in CF treatment
centres or outside hospital settings for many years [284].
Epidemic outbreaks of the same B.cepacia complex in
different CF centres have been traced to traveling patients
with CF [285,286].
There is limited evidence for cross-infection of other CF
related pathogens [287].
7.3. Prevention of cross-infection
If guidelines for infection control are followed including
separation of infected patients from uninfected, susceptible
patients and the implementation of hygienic measures,
prevention of cross-infection has been demonstrated. Based
on mathematical models [120], the risk for cross-infection
increases with increasing numbers of patients attending the
CF centre. In addition, it increases with the contact density
between infected and non-infected patients and if the
prevalence of infected patients is >20%. Therefore, smaller
centres with low prevalence of infected patients and where
the contact density is low may not have detectable cross-
infection, whereas larger centres with high prevalence of
infected patients and with high contact density may expe-
rience such cross-infection more often. To prevent cross-
infection, particularly in larger centres, regular culturing of
CF related pathogens, calculation of incidence rates and
bacterial typing are demanded. If incidence rates are high or
increasing, and typing suggests spread, analysis of possible
sources and routes of cross-infection is required, followed
by the implementation of appropriate infection control
methods.
Segregation of patients has been shown in several CF
centres to prevent cross-infection with P. aeruginosa. For
instance, whereas a cohort of 22 patients with CF shared the
same P. aeruginosa clone, probably acquired nosocomially,
none of the 24 patients with CF of another cohort who had
been segregated for eight years, acquired this clone [274].
By segregating patients with CF, an epidemic of a multiple
antibiotic resistant strain of P. aeruginosa was stopped
[120]. Similarly, an early B. cepacia complex epidemic
was stopped segregating patients with CF [288]. On the
other hand, centres that have failed to practice segregation
have documented on-going transmission of epidemic clones
[284,289]. Due to the accumulated evidence of cross-infec-
tion between patients with CF, the attendance of patients
with CF at summer camps and other social events has been
discouraged. However, this recommendation is not univer-
sally supported [290]. To reduce the rate of cross-infection
in hospitals, in some centres patients with CF are forced to
wear surgical masks, however, there is currently no evi-
dence has been presented that this measure is effective.
Hygienic measures to decontaminate environmental reser-
voirs of P. aeruginosa including nebulizers and other
medical equipment, sinks, toilets and dental tubings, have
been recommended [201] and some of these have been
shown to be efficient [291]. Hand disinfection for patients
with CF and hospital personnel has been stressed [6,200].
The use of waterless antiseptic hand rubs is more effective
than handwashing using water and plain or antimicrobial-
containing soap [292]. Unfortunately, adherence by HCWs
to recommended practices is low [268] and specific educa-
tional programs with active support of healthcare adminis-
trators are needed to overcome barriers to adherence with
infection control guidelines at CF centres. For home thera-
py, patient guidelines concerning hygiene and physiothera-
py need to be established [207] including monitoring of the
necessary equipment. A number of guidelines and consen-
sus reports for effective infection control programs have
been published [5,6,55,293].
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prevented by mupirocin [294]. Table 6 lists hygienic meas-
ures to prevent cross-infection in patients with CF and
Tables 7a and 7b, the principles of patient-cohorting.
7.4. Physiotherapy and physical activity/exercise
Modern physiotherapy (PT) in CF consists of an individ-
ually tailored regimen incorporating inhalation therapy
[5,295,296], airway clearance and physical exercise [297].
The components and dosage (duration and number of treat-
ments per day) of the individualized therapeutic regimen will
differ according to the state of the patient. During acute
exacerbations the regimen may be more complex and inten-
sified compared to baseline maintenance PT therapy. The
timing of the different parts of the PT package in relation to
each other, to meals and daily routines is essential in
achieving optimal treatment with minimal side effects.
Ongoing patient education, regular patient/physiotherapist
communication and assessment, adherence with quality
treatment and early identification of exacerbations are crit-
ical. Selection of the components of the regimen is made up
of cooperation with the patient/family taking into account
pulmonary pathophysiology, age, social, economic, cultural,
lifestyle considerations and personal choice to optimize
quality of treatment and adherence.
PT is not only rehabilitative but rather aims to remove
viscous airway secretions thus compensating for impaired
mucociliary clearance and minimizing the lung disease
process [298,299]. Many different types of PT are practised
around the world with asymptomatic and symptomatic
infants, however, few of these techniques are evidence
based [300]. The assessment of any impact of physiotherapy
on lung disease is difficult in long-term studies, since other
treatment strategies of the care package are constantly
applied and developed continuously. Therefore, randomized
controlled trials assessing the effects of PT versus no PT on
patients with CF have not been performed [301]. Conclu-
sions concerning the efficacy of physical training in CF are
limited by the small number of randomized controlled trials
and the fact that physical training is already part of standard
treatment [302]. Since daily PT requires much discipline
from patients and parents and may adversely affect the
relationship between parents and child randomized trials
to assess the preventive effect of physiotherapy are urgently
needed. Particularly, there is a need to assess the preventa-
tive effect of physiotherapy on the development of mucus
Table 6
Hygienic measures to prevent cross-infection in patients with CF
(1) Establishing separate cohorts inside and outside of the hospital.
(2) Implementing hygienic measures e.g.:
Hand hygiene of patients, staff, visitors
prohibition of sharing nebulizers, tooth-brushes, drinking glasses, etc.
appropriate disposal of contaminated articles
cleaning followed by sterilization or high-level disinfection of non
disposable equipment including nebulizers
sink disinfection using heating devices in hospitals
daily cleaning of patient’s room by disinfecting soaps
Table 7a
Principles of patient-cohorting
P. aeruginosa B. cepacia complex MRSA S. maltophilia A. xylosoxidans MOTT
a
Cohorting + + +  
Number of cohorts 4
b n
c 1
Universal hygienic precautions + + + + + +
Wards + + +  
Outpatient clinic + + +  
a Mycobacteria other than tuberculosis.
b No P. aeruginosa, intermittent P. aeruginosa colonization, chronic P. aeruginosa infection with sensitive strains of P. aeruginosa, chronic infection with
multiply resistant strains of P. aeruginosa.
c Each patient is isolated in a single cubicle.
Table 7b
Practical aspects of cohorting patients with and without P. aeruginosa and
B. cepacia complex
Wards #1 #2 #3: single
cubicles
No P.a./Bc +
Intermittent P.a. +
Chronic P.a.,
sensitive to
antibiotics
(+)
a +
a
Chronic P.a.,
multiresistant
+
Intermittent/
chronic Bc
+
Outpatient clinic Monday Tuesday Wednesday Thursday Friday
No P.a./Bc + + +
Intermittent P.a. + + +
Chronic P.a.,
sensitive
+
Chronic P.a.,
multiresistant
+
Intermittent/chronic Bc: Isolation room with separate waiting room and
entrance-cleaned after each patient.
a Patients without P.a. can be admitted to ward #1 at the same time as
patients with intermittent P.a. provided that the latter are on prolonged anti-
P.a. treatment (usually inhaled colistin and ciprofloxacin or inhaled
tobramycin), but they must not share rooms. Patients with chronic P.a.,
fully sensitive to antibiotics can be admitted to ward #1 provided there are
no other CF patient at the same time. Otherwise, they will be admitted to
ward #3 (isolation cubicles).
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oxic environment [107,109] and early HRCT signs of lung
destruction [143] in infants.
Support for PT is derived from a study showing that a 3-
week period without PT led to a worsening in lung function
status [303]. Combining IV antibiotic treatment with inten-
sified airway clearance has been shown to improve lung
function more than IV antibiotic treatment alone [304].
Although it has been suggested that very young CF infants
should receive the full range of PT treatments as applied in
older patients [305], differences concerning anatomy, phys-
iology, gastro-oesophageal function and respiratory behav-
iour between very young infants and adults with CF demand
more specific strategies [306]. A higher gastro-oesophageal
reflux (GOR) index and longer reflux episodes have been
demonstrated in P. aeruginosa-infected versus non-infected
infants [307]. Since certain airway clearance techniques
including positioning and manual techniques are thought
by some to provoke episodes of GOR [308,309], it has been
recommended that asymptomatic infants with CF should not
be treated in head down positions [310]. However, others
would contest the effect of posture on GOR [311].
The positive expiratory pressure (PEP) technique was
found to be as effective as postural drainage. Parents and
infants, however, preferred the PEP technique [312]. Phys-
ical activities combined with assisted autogenic drainage
manoeuvres showed no provocation of GOR and is an
alternative airway clearance technique for infants and small
children [313].
Physical exercise was gradually introduced as part of the
CF treatment in the late 1970s/early 1980s and collective
experience from centres using it suggests beneficial effects
in terms of physical capacity and function. Fragility frac-
tures have been reported in an adult CF population [314].
Many patients showed evidence of thoracic vertebral defor-
mity; bone mineral density was positively related to phys-
ical activity and lung function [314]. Children and
adolescents with CF, despite having good lung function,
have been shown to be engaged in less vigorous spontane-
ous physical activity than their non-CF peers [315]. Thus,
physical activity/exercise, appied very early, may be bene-
ficial. Exercise should include working capacity training,
mobility exercise, muscle strengthening and stretching in
order to maintain good posture and musculo-skeletal func-
tion. Chest mobility allows effective airway clearance, and
good posture reduces the risk of back pain and spinal
complications. Physical activity/exercise can be used as part
of airway clearance.
Repeated evaluation of the different components of the
physiotherapy package is essential for optimal therapy and
adherence to treatment. Optimal therapy requires physio-
therapists to have specialist knowledge, skills and experience
of the different elements of the physiotherapy care package.
Furthermore, the ability to develop good rapport, a concor-
dant relationship with each patient and ongoing continuity of
care are crucial for optimal results in the long-term.
8. Questions and answers
Answers to the following questions have been graded
into categories given in Tables 8 and 9 by the participants of
the conference.
(1) Heterozygote screening, prenatal screening and neo-
natal screening: what is recommended?
Heterozygote screening for CF, either preconceptional or
prenatal has a variable and often low uptake in different
countries andwholepopulationheterozygote screening isnot
recommended (BIII). When prenatal heterozygote screening
is offered, prenatal diagnosis should be available (AIII).
When prenatal screening is carried out for other diseases,
screening for CF should routinely be offered to the pregnant
woman (AIII). Before offering heterozygote screening, gen-
eral social and genetic counselling is needed. Neonatal
screening is recommended as it offers the opportunity to
prevent malnutrition and chronic respiratory infection by
early interventions (AI). Also one of the main advantages
of newborn screening is that it enables the parents to take
informed choices about future pregnancies (AII).
(2) Does newborn screening improve patients’ clinical
status and does it lead to earlier intervention in patients with
CF?
The clinical status of patients with CF diagnosed by neo-
natal screening improves nutritional and pulmonary status,
provided that they receive approved standards of care (AI).
(3) What is the adequate standard of care after a CF
diagnosis necessary to provide clinical benefit?
Approved standards of care are defined by international
consensus groups or national consensus groups of CF
specialists. Patient numbers in CF centres should be at least
approximately 50 patients or more (CIII). The care should
be provided by an adequately resourced multidisciplinary
CF team (BIII).
(4) How does diagnosis of CF lung infection differ from
that of other patients with lung disease?
CF lung disease is part of a multisystem disease and may
have more severe consequences for life expectancy than
other causes of lung infection. The CF lung is unique and
highly susceptible to colonization/infection with a large
number of unusual environmental opportunistic organisms.
Specialist microbiological facilities are required for diagno-
sis and should be used to provide state-of-the art surveil-
Table 8
Definition of categories reflecting the scientific strength of recommenda-
tions for or against its use
Category Definition
A* Good evidence to support a recommendation for use
B Moderate evidence to support a recommendation for use
C Poor evidence to support a recommendation for or against use
D Moderate good evidence to support a recommendation
against use
E Good evidence to support a recommendation against use
* From Refs. [316,317].
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infection control (AII). In addition to sputum culture for
bacterial pathogens, continuous, standardized antibody
monitoring for P. aeruginosa is considered by some to be
helpful (BII). Detection of any respiratory pathogens should
prompt antimicrobial treatment (AII).
(5) What are the benefits of CF patient registries in
Europe and how are registries implemented?
CF registries are important tools to monitor and improve
standards of care (BIII). Benefits include the generation of
reports to individual institutions and patients, formation of
quality groups with quality ranking, learning from the best
centres, recognition of alarm signals for early therapeutic
intervention and the creation of decision trees. The existing
national registries should unite into a European registry
(BIII).
(6) What is early intervention?
If there is clinical, bacteriological or radiological evidence
of infection (this includes culture of a known pathogen) or
inflammation, an intervention is indicated, but a clear diag-
nosis cannot always be made in non-sputum producing
patients (AII). Respiratory cultures should be obtained at
least every 3 months or ideally every month and in the
presence of any increase in respiratory symptoms (AII).
(7) How is eradication of major bacterial pathogens in CF
defined, how it is achieved and how long are patients with
CF free of bacterial pathogens after eradication therapy?
Since bacteria can persist in low concentrations insome of
the airways, it is nearly impossible to prove eradication.
Repeated negative respiratory cultures (at least three) within
a 6-month period months after cessation of treatment in the
presence of negative specific antibodies is practical evidence
for eradication of a bacterium (BIII). There is limited infor-
mationavailableonlyfordifferentapproachestotreatearlyP.
aeruginosa infection and even less for most other bacteria.
The duration of therapy may be important as shown for the
combination of ciprofloxacin/inhaled colistin, where 3-
month versus 3-week treatment was associated with an
increase of the median time to recurrence/reinfection from
9 to 18 months compared with historical controls (BII). Early
P.aeruginosa infection has been successfully eradicated with
inhaled colistin or tobramycin, oral ciprofloxacin/inhaled
colistin or tobramycin, intravenous treatment alone or in
combination with inhaled colistin or tobramycin (AII). The
optimal form of therapy is not established. In spite of early
and aggressive treatment, it may not be possible to eradicate
bacterial pathogens from airways of patients with CF, result-
ing in chronic bacterial infection. A course of anti-staphylo-
coccal therapy for at least 2 weeks is likely to eradicate a new
infection with S. aureus in the majority of patients. It is
important to try to eradicate other pathogens such as MRSA,
B. cepacia complex, S. maltophilia, A. xylosoxidans and
other Gram-positive and Gram-negative bacteria using anti-
biotics based on individual sensitivity tests (AII).
(8) How does the bacterial phenotype influence eradica-
tion from CF airways?
Early P. aeruginosa colonization/infection usually occurs
with non-mucoid strains that are more amenable to eradi-
cation (AI). Even early infection with mucoid P. aeruginosa
may be eradicated in individual cases and attempt to
eradicate should be made (BII). However, it is usually
impossible to eradicate chronic mucoid P. aeruginosa in-
fection in patients with CF because of its biofilm mode of
growth. Small colony variants of S. aureus have also been
found to be resistant to eradication.
(9) How does antibiotic resistance influence eradication
from CF airways?
In the absence of cross-infection with multiresistant
strains, nearly all newly detected strains of P. aeruginosa
are sensitive to the majority of anti-pseudomonal antibiotics
(AII). Therefore, resistance in early infection is less of a
problem compared to chronically infected patients. Inherent
resistance (in contrast to acquired resistance) remains a
problem for MRSA, B. cepacia complex, S. maltophilia
and A. xylosoxidans and this causes difficulties in eradication
(AII).
(10) If eradication cannot be achieved what is the optimal
management for the major bacterial pathogens in CF?
If the initial therapy for early colonization/infection does
not eradicate the organism, another treatment regimen,
including intravenous antibiotics should be administered
(BII). It is unclear how many different treatment regimens
should be used before it is considered impossible to erad-
icate the organism in a given patient. If the patient becomes
chronically infected with P. aeruginosa, treatment should be
given according to the previous ECFS consensus document
(Do ¨ring et al. [5]) (BIII).
(11) Are prophylactic antibiotics effective to prevent
bacterial lung infection?
There is some evidence that prophylactic anti-staphylo-
coccal antibiotic treatment is effective in reducing the rate of
S. aureus positive respiratory cultures (AI). There is also data
suggesting that this form of therapy especially with oral
cephalosporins may increase the risk of P. aeruginosa infec-
tion (AI). As the clinical benefit of long-term prophylactic
anti-staphylococcal antibiotic treatment remains unproven,
there is currently insufficient evidence to recommend this
approach.However,thereislimited evidenceofbenefitinthe
first2years oflife(CIII).InthecaseofP.aeruginosa,thereis
Table 9
Categories reflecting the quality of evidence on which recommendations are
based
a
Grade Definition
I Evidence from at least one properly randomized, controlled trial
II Evidence from at least one well-designed clinical trial without
randomization, from cohort or case-controlled analytic studies
(preferably from more than one centre), from multiple time-series
studies, or from dramatic results in uncontrolled experiments
III Evidence from opinions of respected authorities, based on
clinical experience, descriptive studies, or reports of expert
committees
a From Ref. [316].
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inhaled gentamicin in patients with CF to suggest that
prophylacticantibiotictherapymaybeeffectiveinpreventing
P. aeruginosa colonization/infection (CII). In view of the
therapeutic burden of prophylactic treatment and the evi-
dence-based efficacy of early intervention therapy, the pro-
phylactic approach is not currently recommended (DIII).
(12) What is the background for airway inflammation in
CF, how it is defined and which markers are useful to
monitor it?
Airway inflammation is an early phenomenon in CF and
it is clear that the inflammatory response to microbes and
other pro-inflammatory stimuli is augmented and prolonged.
Airway inflammation, which is a major cause of progressive
lung damage, is largely neutrophilic, with multiple complex
mechanisms. At present, there are no reliable non-invasive
routine markers for early inflammation, and clinicians have
to rely on clinical signs and symptoms. Pseudomonas
antibody levels correlate well with the severity of chronic
P. aeruginosa infection (AIII).
(13) Which anti-inflammatory drugs are clinically effec-
tive in patients with CF?
Firstly, any underlying cause must be treated energeti-
cally (AIII). Long-term corticosteroidal drugs have proven
clinical effect, but have an unacceptable profile of side
effects on prolonged use (EI). There is conflicting evidence
of benefit for inhaled steroids outside the context of CF
complicated with asthma (CII). Macrolides appear to be
safe, and improve lung function and reduce exacerbations in
P. aeruginosa-infected patients (BI), but a relevant anti-
inflammatory effect of these drugs in CF airway is unproven
(BII). Ibuprofen has shown clinical benefit in one trial (AI),
but there are concerns about side effects and the need for
monitoring of blood levels (AII).
(14) In which age groups should anti-inflammatory drugs
be applied?
There is currently no evidence to recommend preventive
anti-inflammatory therapy, particularly in the early years of
life. The ibuprofen study suggested increased benefit in less
advanced disease, in patients who were nonetheless already
chronically infected, suggesting that early anti-inflammatory
therapy may be beneficial (BI). However, the risk of side
effects in the well-treated child for a long period must also
be considered (CIII). Effective use of proven treatments for
underlying causes, in particular infection, is mandatory (AI).
This involves close monitoring of young infants in partic-
ular (BII).
(15) Is early treatment with therapy aiming to im-
prove mucociliary clearance effective in maintaining lung
function?
The data suggest that introducing dornase alpha early in
the disease may be beneficial (AI). Although the safety of
dornase alpha has been established during 2 years’ contin-
uous treatment of children with CF, there is no longer-term
safety data particularly in the context of the growing lung
(BII). There is no evidence to support the use of any other
mucoactive agent such as hypertonic saline or N-acetyl-
cysteine in the early stages of the disease (CIII).
(16) What are the major reservoirs of CF-relevant micro-
organisms and which routes of transmission of bacterial
pathogens to patients with CF have been determined?
For the majority of patients with CF worldwide, the
source of their P. aeruginosa infection cannot be determined.
Potential reservoirs are some natural environments, other
infected patients with CF and contaminated hospital settings
(AII). The relative importance of these reservoirs differs
between centres. Current epidemiological data suggest that
each of these reservoirs may contain CF-related pathogens
which may be transmitted by one or more routes. Therefore,
transmission routes are complex as given in Table 10 (AII).
(17) How is evidence obtained for a given transmission
route?
Evidence is obtained by microbiological surveillance,
prospective studies and genotyping of isolates from patients
with CF and suspected environmental reservoirs (AI). Typ-
ing data are evaluated in conjunction with epidemiological
data, which may include case-control studies, and the
impact of specific infection control procedures (AI).
(18) Can cross-infection occur in patients with CF?
Yes, there is compelling evidence, that cross-infection
can occur between patients with CF with regard to the B.
cepacia complex and some strains of P. aeruginosa, directly
or indirectly (AI). Evidence for cross-infection is limited or
lacking for other CF-related pathogens (AII).
(19) How is cross-infection prevented?
Table 10
Potential reservoirs of microbial pathogens in CF and possible transmission
routes
Waste water (sink drains, toilets, showers)
Seawater near sewage outfalls and polluted river outlets
Medical devices and equipment containing water including equipment for
testing lung function and for inhalation therapy
Ineffectively chlorinated swimming pools and whirlpools
Air humidifiers
Tubing in dentist’s units
Infected patients
Contaminated healthy individuals
Soil
Plants
Vegetables
Routes of transmission
(1) Aerosolized bacteria colonize airways directly by aspiration or indirectly
via hand contamination. Note: Close contact necessary (within 1 m),
short-lived bacteria in aerosols and on hands, high bacterial concen-
trations in environmental sources.
(2) Ingestion of contaminated food colonizes airways or gastrointestinal
tract.
(3) Direct contact to contaminated healthy individuals or infected patients.
Note: Increasing duration and closeness of contact increase the risk of
transmission. Sputum enhances bacterial survival.
(4) Infection, or cross-infection, with P. aeruginosa or with B. cepacia
complex may occur in hospitals and outside the hospital, i.e., at home, at
school, during travel, in restaurants, in public places, during summer
camps or other meetings.
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prevented by employing various degrees of patient segrega-
tion inside and outside hospitals as described in Table 10
(AII). Practical approaches to segregation may differ from
centre to centre, however, certain minimal standards, sup-
ported by appropriate microbiological surveillance, should
be implemented in the CF centres with the goal of preventing
exposure of non-infected patients to patients infected with
potentially contagious organisms (AII). Segregation of CF
siblings from each other is not recommended, since it would
interfere with normal family life (AIII). Cross-infection can
also be reduced by good hygiene as described in Tables 7a
and 7b (AIII). This applies to the hospital environment, the
hospital staff and the patients and their relatives. Education
of the staff, the patients and their relatives with regard to the
need for segregation and hygiene is mandatory (AIII). The
risk of cross-infection is also reduced by implementing
means to reduce the prevalence of infection (AII).
(20) Is chest physiotherapy justified as part of the care
package to prevent a decline in lung function?
Chest physiotherapy is justified in all CF patients starting
from diagnosis of the disease, since it is the primary
physical method to compensate for impaired mucociliary
clearance by removing viscid and inflammatory material
from the CF airway (BII). Individually tailored approaches
to chest physiotherapy are needed in different age groups
and for individual patients (AII).
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